

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

María del Carmen Manzano-Robleda,* Victoria Ornelas-Arroyo,* Tonatiuh Barrientos-Gutiérrez,** Nahum Méndez-Sánchez,*** Misael Uribe,*** Norberto C. Chávez-Tapia*

* Obesity and Gastrointestinal Diseases Unit. Medica Sur Clinic & Foundation, Mexico City.

** National Institute of Public Health, Cuernavaca, Mexico.

*** Liver Research Unit. Medica Sur Clinic & Foundation. Mexico City, Mexico

ABSTRACT

Background. Treatment of hepatitis C virus (HCV) infection with newer direct-acting antivirals is unrealistic in some countries because of the lack of availability. **Aim.** Assess benefits and harms of boceprevir (BOC) and telaprevir (TLV) in treatment of genotype 1 HCV infection, and identifying subgroups with most benefit. **Material and methods.** Search from 2009-2013 in PubMed, EMBASE, and "gray literature" of published and unpublished randomized trials reporting sustained viral response (SVR) or adverse events (AE) with BOC or TLV + pegylated interferon and ribavirin (PR) in HCV-infected patients; cohorts or case reports for comparison protease inhibitors (PI), evaluation of predictors of SVR, and resistant variants. Cochrane guidelines were applied. Comparisons between PI + PR vs. PR were performed. Main outcomes were expressed as risk-ratios with 95% CIs. Meta-regression and trial sequential analysis were performed. **Results.** 33 studies (10,525 patients) were analyzed. SVR was higher for PI + PR (RR, 2.05; 95% CI 1.70-2.48). In meta-regression, previously treated patients exhibited greater benefit from PI + PR (RR, 3.47; 95% CI, 2.78-4.33). AE were higher with PI + PR (RR, 1.01; 95% CI, 1-1.03; NNH 77.59), also the discontinuation rate (RR, 1.69; 95% CI, 1.36-2.10, NNH, 18). Predictors of SVR were IL-28 TT, nonblack race, low viral load, age, no cirrhosis, statin use, undetectable viral load at the first anemia episode and at week 2 of treatment, and low IL-6 levels. In conclusion SVR was higher in patients treated with PIs, patients previously exposed to PR showed superior response rates. Specific predictors will determine the best candidates for treatments that will offer real-life therapeutic alternatives.

Key words. Direct acting antiviral. Sustained virological response. Protease inhibitor. Adverse drug event. Evidence based medicine.

BACKGROUND

The treatment of hepatitis C virus (HCV) infection has been revolutionized by the advent of new drugs such as direct-acting antivirals (DAAs) including NS3/NS4A serine protease inhibitors (PIs), NS5A inhibitors, nucleoside and nonnucleoside NS5B polymerase inhibitors, and cyclophilin inhibitors. Clinical guidelines have tried to keep pace with these developments and have recommended the use of therapeutic options that produce the largest sustained virological response (SVR), with the lower

risk of adverse events (AEs), in the shortest time. Such options include sofosbuvir and newer drugs.¹

Although this rationale is impeccable from a therapeutic standpoint, its translation to real-life conditions seems problematic at best. The high cost of the latest therapeutic options represents a major barrier for the adoption of these guidelines in low- and middle-income countries, where more than 80% of the HCV-infected patients live.² Thus, less effective treatments will be part of common clinical practice in most countries, and high-quality data are needed to offer the best realistic therapeutic options.

Although boceprevir (BOC) and telaprevir (TLV) were approved in 2011, the current guidelines for the treatment of chronic genotype 1 HCV infection no longer recommend their use for the initial treatment or in patients who relapse after treatment with pegylated interferon plus ribavirin (PR).³ Yet, PI+PR and PR alone have produced average SVRs of 67 and 34%, respectively, which might be

Correspondence and reprint request: Norberto Chávez-Tapia, M.D.
Puente de Piedra 150, Toriello Guerra, Tlalpan, 14050, Mexico City.
Tel.: 5424-6892
E-mail: nchavezt@medicasur.org.mx

*Manuscript received: July 19, 2014.
Manuscript accepted: August 9, 2014.*

optimized according to the well-defined predictors of a response to tailor the treatment schema to the best candidates.^{4,5} Systematic reviews and meta-analyses have demonstrated a higher SVR in genotype 1 patients treated with the first approved DAAs, BOC and TLV.⁶⁻⁸ However, previous studies have fallen short in identifying the best candidates for PI + PR treatment, in formally testing the differences in SVRs between different PIs, and in identifying areas in which more research is needed to personalize treatment and optimize more affordable therapeutic options.

The aim of this systematic review and meta-analysis is to assess the benefits and harms of PIs in the treatment of genotype 1 HCV infection. We focused on identifying subgroups of patients who could benefit the most from this therapeutic approach, and we searched for an evidence-based framework for clinical decision-making that could be applied to those health-care systems to which the current clinical guidelines will not apply. The secondary aims were to analyze differences between PIs and to define opportunity areas for future research.

MATERIAL AND METHODS

Two authors (N.C.T. and M.C.M.R.) independently performed a comprehensive electronic search of papers published from January 2009 to November 2013 using the PubMed and EMBASE databases to identify any study that included the use of BOC or TLV in combination with PR and that reported the SVR, safety, viral response predictors, resistant variants, or a comparison between the new drugs (BOC and TLV) and dual-therapy (PR). Response-guided therapy was not included.^{9,10}

The key words used for the search were *hepatitis C virus genotype 1 infection, boceprevir, telaprevir, protease inhibitor, sustained virological response, adverse event, predictor of response, and resistant-associated variants*. The search was limited to the English language and human adults. Manual searches of meeting abstracts from January 2011 from November 2013 were also conducted for The Liver Meeting, The International Liver Congress, *Digestive Disease Week*, and Annual Scientific Meeting of the American College of Gastroenterology. To evaluate the efficacy of BOC or TLV *vs.* PR only, randomized clinical trials were included. To compare BOC + PR *vs.* TLV + PR, randomized clinical trials and cohort studies were included. To assess the safety, predictors of response, resistant variants, randomized trials, cohort studies, and case reports were included. The exclusion criteria included use of a PI other than BOC and TLV, incomplete data,

nonconcomitant use of PR, and studies in children, animals, or *in vitro*. In case of disagreement, the full article was retrieved and inspected independently by the two authors; when disagreement persisted, the authors of the report were contacted. Three authors (N.C.T., M.C.M.R., and V.O.A.) extracted the data of the included trials. In case of disagreement, the decision was made by consensus between the three authors or by contacting the authors of the report. Trials were identified by the last name of the first author and year of publication.

The primary outcome was an SVR, which was defined as a negative viral load at week 12 or 24 after the end of treatment. If both time points were reported, the 24-week viral load was preferred. Secondary outcomes were the frequency and type of AEs, determination of the predictors of SVR, and resistant variants to BOC or TLV.

For the quality assessment of the randomized controlled trials (RCT), two authors (N.C.T. and V.O.A.) evaluated the risk of bias of each trial using the Cochrane Collaboration's risk of bias tool and a predesigned assessment form.¹¹ Seven domains were considered for bias evaluation: sequence generation, allocation concealment, blinding of participants and personnel, outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. The evaluation considered three possibilities: low risk of bias, high risk of bias, or unclear risk of bias. The quality of cohort studies was evaluated by two authors (N.C.T. and V.O.A.) by applying the modified Newcastle-Ottawa scale.¹² This scale comprises eight items: representativeness of the average HCV-infected population, large sample size, selection of the unexposed cohort, definitive diagnostic confirmation, comparability of the cohorts on the basis of the design or analysis, adequate length of follow-up for outcome to occur, clear information on the length of follow-up, and attrition rate. A score of ≥ 6 points was considered high quality, 4-5 medium quality, and ≤ 3 low quality.

Statistical analysis

Differences in SVR were calculated using intention-to-treat analysis by calculating the risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity assessment was conducted using a standard Q test ($P < 0.1$) and I^2 test ($>25\%$). Subgroup analyses were conducted to explore for potential sources of heterogeneity by comparing the use of BOC + PR *vs.* TLV + PR, naïve *vs.* previously treated patients, and patients coinfecting with human immunodeficiency

ciency virus (HIV) *vs.* non-HIV infected. These factors were then introduced into a meta-regression, with SVR as the outcome, to identify the main sources of heterogeneity while adjusting for covariates (Stata 13.0; StataCorp, College Station, TX). After identification of significant sources of heterogeneity, fixed-effect estimates were calculated in homogeneous subgroups, and random-effects estimates

were used to estimate global measures of effect. Data management and analysis were conducted in RevMan 5.2 (The Nordic Cochrane Centre, Copenhagen, Denmark), and the meta-regression was conducted in Stata 13.0.

To assess the reliability of the meta-analysis of SVR with PI + PR, the required information size was calculated by trial sequential analysis (TSA,




Figure 1. Study selection process of the 33 studies included, some of them was used in more than one outcome variable.

Table 1. Characteristics of the 33 analyzed studies.

Reference	Author	PI	Design (Name)	Country	n	Ef	Sf	Pr	Rt
14	Hezode	TLV	Phase 2, randomized, partial double-blind, placebo-controlled (PROVE 2)	France, Germany, England, Austria	323	*	*		*
16	McHutchinson	TLV	Phase 2, randomized, partial double-blind, placebo-controlled (PROVE 1)	USA, England	250	*	*		
15	McHutchinson	TLV	Phase 2, randomized, partial double-blind, placebo-controlled (PROVE 3)	Germany, Canada, USA, Netherlands	453	*	*		
18	Bacon	BOC	Clinical trial (RESPOND 2)	USA, France, Germany, Spain	403	*	*		
19	Poordad	BOC	Clinical trial (SPRINT 2)	USA, Italy, Germany, France	1,472	*	*	*	
20	Jacobson	TLV	Clinical trial (ADVANCE)	England, USA, France, Poland, Italy, Austria, Israel, Argentina, Canada, Germany	1,088	*	*		
32	Sulkowski	BOC	Cohort	France, USA, Israel	1,097		*		
22	Zeuzem	TLV	Clinical trial (REALIZE)	Germany	662	*	*		
17	Sulkowski	TLV	Clinical trial Phase 2 trial	USA, Germany, France	60	*			
40	Thomas	TLV	Case report	Holland, USA	14				*
23	Mallolas	BOC	Clinical trial	France, Argentina, USA	99	*	*		
26	Sulkowski	TLV	Clinical trial, phase 2	Spain, Germany, France, England	62	*	*		
41	Pinson	TLV	Case report	France	17				*
34	Lawitz	BOC	Clinical trial	USA	687			*	
24	Kumada	TLV	Clinical trial	Japan	220	*	*		
42	Volpe	BOC & TLV	Case report	USA	500				*
27	Coilly	BOC & TLV	Cohort	France	37	*			
28	Hezode/Fointaine	BOC & TLV	Cohort (CUPIC)	France	674	*			
43	Velazquez	BOC & TLV	Case report	England	59				*
44	Messina	BOC & TLV	Case report	Italy	74				*
37	Ogawa	TLV	Case report	Japan	406			*	
45	Galmozzi	BOC & TLV	Case report	Italy	36				*
39	Hoffmann	BOC & TLV	Case report	Brazil	68				*
30	Backus	BOC & TLV	Cohort	USA	859	*			
29	Akiyama	BOC & TLV	Cohort	Hawaii	59	*			
31	Singh	BOC & TLV	Cohort	USA	144		*		
25	Flamm	BOC	Clinical trial	USA, France	201	*	*		
35	Purohit	BOC & TLV	Case report	?	71			*	
46	Cento	TLV	Case report	Italy	12				*
47	Cento	BOC & TLV	Case report	Italy	70				*
36	Asahina	TLV	Case report	Japan	172			*	
33	Karino	TLV	Case report	Japan	94			*	

TLV: telaprevir. BOC: boceprevir. PI: protease inhibitor. n: number. Ef: efficacy. Sf: safety. Pr: predictors of response. Rt: resistant variant mutations.

RM5 Converter, the Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark).¹³ We assumed a 32% RR reduction of the experimental intervention and statistical error levels of 5% for alpha and 20% for beta (80% power), respectively. Whenever the cumulative information size in the meta-analysis was smaller than the required information size, the threshold to maintain statistical significance was calculated with the O'Brien-Fleming boundaries.

To identify the most common AEs, the RR, 95% CI, and number needed to harm (NNH) were calculated.

RESULTS

A total of 356 studies were identified by the initial search strategy, 289 in the supplements of international meetings, 46 studies in PubMed, and 21 on EMBASE. A total of 250 were excluded: 167 were repeated, 49 used a different PI, 8 reported other outcomes, 7 did not report which PI was used, 7 did not report the number of patients, 7 did not report the HCV genotype, 2 did not use concomitant treatment with PR, 2 did not report the methodology, and 1 was conducted on healthy subjects. After a full




Figure 2. A. Summary of risk of bias. B. Quality of cohort studies.




Figure 3. SVR of protease inhibitor plus pegylated interferon plus ribavirin vs. pegylated interferon plus ribavirin.

Table 2. Subgroup analysis of SVR with protease inhibitor plus pegylated interferon plus ribavirin vs. pegylated interferon plus ribavirin.

Outcome	Trials (n)	RR	95% CI	I ² (%)
Boceprevir	4	1.95	1.70-2.22	69.8
Telaprevir	7	1.77	1.61-1.95	78.9
Naive patients	7	1.67	1.54-1.82	0
Pretreated patients	4	3.47	2.78-4.33	0
HCV + HIV coinfection	2	1.83	1.26-2.65	0
HCV mono-infection	9	1.83	1.69-1.98	79

RR: risk ratio. CI: confidence interval.




Figure 4. Comparison of the SVR between boceprevir plus pegylated interferon plus ribavirin vs. telaprevir plus pegylated interferon plus ribavirin.




Figure 5. Trial sequential analysis assuming a 32% relative risk reduction of the experimental intervention and statistical error levels of 5% alpha and 20% beta (80% power).

Table 3. Safety analysis of protease inhibitor plus pegylated interferon plus ribavirin vs. pegylated interferon plus ribavirin in all patients, naïve patients, and pre-treated patients.

	All patients			Naïve			Pre-treated		
	RR	95% CI	NNH	RR	95% CI	NNH	RR	95%CI	NNH
Any AE	1.01	1.00-1.03	77.594	1.01	1.00-1.02	92.40	1.02	1.00-1.05	NC
Anemia	1.67	1.53-1.83	5.286	1.52	1.36-1.70	5.74	2.17	1.70-2.76	4.77
Neutropenia	1.09	1.00-1.18	NC	1.04	0.95-1.12	NC	1.68	1.10-2.56	13.07
Thrombocytopenia	2.25	1.79-2.83	4.373	2.25	1.79-2.83	4.37	—	—	—
Rash	1.53	1.36-1.72	9.482	1.32	1.16-1.51	11.43	2.31	1.79-2.29	6.09
Pruritus	1.39	1.25-1.55	11.469	1.29	1.14-1.46	14.55	1.72	1.38-2.16	6.96
Death	0.82	0.24-2.84	NC	0.6	0.14-2.48	NC	2.52	0.12-51.73	NC
Fatigue	1.02	0.96-1.09	NC	0.96	0.89-1.04	NC	1.17	1.04-1.33	14.07
DC due to AE	1.69	1.36-2.10	18.036	1.34	1.06-1.70	27.56	3.84	2.19-6.75	9.80

AE: adverse event. DC: discontinuation. RR: risk ratio. CI: confidence interval. NNH: number needed to harm.

Table 4. Predictors of sustained viral response.

Reference	Year	Drug	Design	n	Predictor of viral response	SVR, OR (95% CI)
33	2013	TLV	Case report	94	IL-28 TT	16.4 (4.38-61.7)
19	2011	BOC	RCT	1,097	Black vs Nonblack	0.5 (0.3-0.7)
					Baseline HCV RNA ≤ 400,000 IU/mL	3.9 (2.1-7.1)
					Age < 40 y vs. > 40 y	1.5 (1.0-2.1)
					No cirrhosis vs. cirrhosis	2.5 (1.4-4.6)
					Statin use	3.4 (1.1-10.7)
34	2012	BOC	Randomized, multicenter, open-label trial	687	HCV RNA undetectable at the first anemia episode	4.91 (3.2-7.6)
35	2013	BOC & TLV	Case report	71	Undetectable viral load w2	Not expressed
36	2013	TLV	Case report	172	Low IL-6 on treatment levels	Not expressed
37	2013	TLV	Case report	406	IL 28 TT	5.9 (Not available)
					Viral response at w 4	5 (Not available)

TLV: telaprevir. BOC: boceprevir. IL: interleukin. HCV: hepatitis C virus. y: years. EPO: erythropoietin. RibDR: ribavirin dose reduction. w: week. RCT: randomized control trial.

review of 106 potentially eligible articles, 33 met the inclusion criteria and included a total of 10,525 patients; some of the 33 studies were used for the evaluation of more than one outcome (Figure 1). The characteristics of the included studies are summarized in table 1.

The risk of bias and the quality of randomized trials and cohort studies were classified as a low risk of bias with an unclear selection bias in only 4 studies, and medium quality in most of the cohort studies (Figure 2).

Efficacy studies

A total of 16 studies were included for this outcome; 11 were RCTs¹⁴⁻²⁶ that compared PI + PR

with PR, and 4 cohort studies²⁷⁻³⁰ compared BOC + PR with TLV + PR. A total of 6,922 patients were included in the meta-analysis: 5,293 in RCTs and 1,629 in cohorts.

The SVR was higher for PI + PR than for PR (RR, 2.05; 95% CI, 1.70-2.48; I^2 , 77%) (Figure 3). When analyzed separately, the SVR was higher for BOC + PR (RR, 1.95; 95% CI, 1.70-2.22; I^2 , 69.8%) and TLV + PR (RR, 1.77; 95% CI, 1.61-1.95; I^2 , 78.9%) than for PR (Table 2). For the comparison of SVR between BOC + PR vs. TLV + PR, 4 cohorts were analyzed, and a difference on favor to TLV was found (RR 0.82; CI, 0.74-0.91; I^2 78%) (Figure 4).

In the subgroup analysis, treatment-naïve patients had a lower probability of achieving an SVR in the PI + PR vs. PR comparison (RR, 1.67; 95% CI, 1.54-

1.82, I^2 , 0%) compared with previously treated patients (RR, 3.47; 95% CI, 2.78-4.33; I^2 , 0%). This result was confirmed in the meta-regression where naïve patients had lower probability of achieving an SVR than did previously PR-treated patients. This is because the SVR rates in PR-treated patients which receive again PR is very low. This difference explains why the RR for PI + PR was larger in previously PR-treated patients than in naïve patients, even while the SVR for PI + PR in previously treated patients (SVR rate, 62%) was similar to that achieved in naïve patients (SVR rate, 70%).

The SVR for the PI + PR *vs.* PR comparison in HIV-positive and -negative patients did not differ significantly (RR 1.83; 95% CI, 1.26-2.65; I^2 , 0% and RR, 1.83; 95% CI, 1.69-1.98; I^2 , 79%, respectively). In the meta-regression, the only significant factor was the previous use of PR; i.e., naïve patients had a 52% lower probability of achieving an SVR than did previously treated patients (95% CI, 0.38-0.61) (Table 2). The TSA showed beneficial effects of the intervention in achieving an SVR, and the cumulative Z-score crossed the O'Brien-Fleming boundaries (Figure 5).

Safety studies

A total of 11 clinical trials^{14-16,18-20,22-26} and 2 cohort studies^{31,32} were included in this analysis (6,474 patients). The increased risk of exhibiting any AE with PI + PR *vs.* PR was low (RR, 1.01; 95% CI, 1.00-1.03; NNH, 77). The most frequent AEs with PI + PR *vs.* PR were thrombocytopenia (RR, 2.25; 95% CI, 1.79-2.83; NNH, 4.3), anemia (RR, 1.67; 95% CI, 1.53-1.83; NNH, 5.2), rash (RR, 1.53; 95% CI, 1.36-1.72; NNH, 9.48), and pruritus (RR, 1.39; 95% CI, 1.25-1.55; NNH, 11.46). Less frequent AEs were neutropenia, fatigue, and death. The discontinuation rate because of an AE was higher for PI + PR than for PR alone (RR, 1.69; 95% CI, 1.36-2.10; NNH, 18). When compared the AE between pre-treated patients with PR and naïve patients, the NNH is lower for patients previously treated with PR (Table 3).

Studies of the predictors of SVR

A total of 6 studies and 2,902 patients were included to evaluate the predictors of viral response (4 case

Table 5. Resistant variant mutations.

Reference	Drug	n	Type of response failure	Associated variants
14	TLV	323	Relapse Breakthrough	V36A/M, T54A, A156S V36+R155K, A156T
38	BOC & TLV	28	Did not achieve SVR.	B: V36A, T54A, V55A, T54S+R155K T: V36A/M, A156T
40	TLV	14	Did not achieve SVR	T54A/S, V36M
41	TLV	17	Failed to eradicate HCV at week 4 and 12.	V54A, Q80R/K, R155K/T/Q, A156S/T/V, Q80K
39	BOC & TLV	68	Relapse	V36L, T54S and V55A
45	BOC & TLV	36	Partial or null response	V36A, 171V, T72I y Q86
46	TLV	12	RNA decay within the first 24 h.	T54S
47	BOC & TLV	70	Absence of response week 4 Viral failure at 48 h.	T54S, V36L V36M, A156T, R155K V36M+R155K
42	BOC & TLV	500	Predicted resistance.	R155K, V36M, T54S, R155K+V36M, T54S+V55I, R155K+T54S
44	BOC & TLV	72	Natural chains-resistant variants Coinfection HIV.	G1 than G3 (p 0.03) Coinfected HCV/HIV (23%) Monoinfected HCV (63%)
43	TLV	59	Viral failure, drug resistant mutation.	AL155 and V36A NS3

TLV: telaprevir. BOC: boceprevir. NS: not specified. RVR: rapid viral response. G: genotype.

reports and 2 randomized multicenter open-label trials).^{19,33-37} IL-28 genotype TT was reported as a prognostic factor of an SVR in two case report studies by Karino³³ and Ogawa³⁷ with an odds ratio (OR) of 16.46 (95% CI, 4.38-61.78; $P < 0.001$) and 5.93, respectively. In the two randomized multicenter trials, the significant predictors of SVR were: black race (OR, 0.5; 95% CI, 0.3-0.7; $P < 0.001$), baseline HCV RNA $\leq 400,000$ IU/mL (OR, 3.9; 95% CI, 2.1-7.1; $P < 0.001$), age < 40 years (OR, 1.5; 95% CI, 1.0-2.1; $P = 0.03$), no cirrhosis (OR, 2.5; 95% CI, 1.4-4.6; $P = 0.003$), and statin use (OR, 3.4; 95% CI, 1.1-10.7; $P = 0.04$). An undetectable RNA viral load at the first anemia episode had a favorable effect on SVR (OR, 4.91; 95% CI, 3.17-7.61; $P < 0.0001$). Other factors associated with an SVR reported in case reports were an undetectable viral load at week 2 of treatment³⁵ and low levels of IL-6 during treatment³⁶ (Table 4).

Resistant variant studies

A total of 11 studies reported variants associated with PI resistance: 1 RCT,¹⁴ and 10 case reports^{14,38-47} with a total of 1,255 patients. The virus variants associated with relapse were V36A/M, T54A, and A156S; and for breakthrough V36 + R155K and A156T. Comparative cohort studies showed that the variants associated with BOC resistance were V36A, T54A, V55A, and T54S + R155K, and those for TLV were V36M, V36A, and A156T. Volpe⁴² reported resistant mutations for TLV and BOC in 500 clinical samples and found a predetermined resistance in 23% of the patients with viral genotype 1a and 24% with genotype 1b. The most common variants were R155K (12.8%), V36M (11.6%), T54S (4.2%), R155K + V36M (9.8%), T54S + V55I (1.4%), and R155K + T54S (1.6%) (Table 5).

DISCUSSION

The present systematic review and meta-analysis aimed to assess the benefits and harms of PIs in the treatment of genotype 1 HCV infection. We focused on the identification of subgroups of patients who could benefit the most from this therapeutic approach. The TSA confirmed a higher SVR with the use of PI+PR compared with PR, and meta-regression showed a greater benefit in patients previously treated with PR. The addition of some variables would help in the personalization of PI. This finding should be considered within the context of the prob-

lem that newer DAAs are not available or affordable in all countries. Because patients treated previously with PR have a good SVR with BOC or TLV, the initial use of a PR could be feasible, thereby reserving BOC or TLV as an alternative and allowing the newer drugs to be reserved for selected patients. However, the individual patient characteristics should guide the selection of the available therapeutic options.

The TSA on the available data confirmed the certainty about the overall SVR of treatment with PI + PR *vs.* PR. This may move the analysis to other important outcomes that could help the clinician select the best candidates for this therapeutic approach. In a previous meta-analysis, Park et al suggested that PI + PR therapy may be more effective in patients treated previously with PR than in naïve patients.⁶ This is surprising considering that the combination of PI + PR should be at least as effective in naïve patients because the effect of a PI should add to the effect of PR. This counterintuitive finding could be attributable to confounding because Park, *et al.* stratified according to the previous treatment, but did not control for other important factors, such as the presence of HIV infection, kind of PI (BOC or TLV), kind of study (first study or confirmatory study), and whether patients were naïve to PR treatment. For that reason, we conducted a meta-regression to control for these potential sources of heterogeneity. The meta-regression confirmed the results of Park et al because naïve patients had a 52% lower probability of achieving an SVR than did previously PR-treated patients. The explanation for this finding resides in the SVR rates of the control groups, which were treated with PR and not with placebo. PR-treated patients have a very low probability of achieving an SVR with a new round of PR treatment (SVR rate, 17%), whereas naïve patients treated with PR have a much higher probability (SVR rate, 41%). This difference explains why the RR for PI + PR was larger in previously PR-treated patients than in naïve patients, even while the SVR for PI + PR in previously treated patients (SVR rate, 62%) was similar to that achieved in naïve patients (SVR rate, 70%). Therefore, the apparent difference between naïve and previously PR-treated patients was only observable in relative but not in absolute terms.

There was sufficient information to identify differences between patients treated with BOC and TLV, being the patients treated with TLV the most benefited when SVR was evaluated, even including the study from Backus³⁰ were an unbalanced in baseline characteristics, particularly for cirrhosis prevalence.

Some predictors of an SVR in patients treated with PI + PR, such as the IL-28b genotype, level of fibrosis, rapid viral response, and viral load, have been reported.⁷ We also found undetectable HCV RNA at the first anemia episode, undetectable HCV RNA at 2 weeks of treatment, IL-6 levels, and statin use to be important predictors of an SVR. Most of these variables are easily assessed in common clinical practice and could help clinicians individualize treatment.⁴⁸ However, the quality of the evidence regarding these predictors is limited, and more robust studies may be needed to confirm them.

Finally, we identified important areas for future research. We found 11 studies with the same associated resistance variants as those reported by previous reviews, such as V36A/M, T54A, V55A, R155K/T/Q, A156S, A156V/T, and V170A for BOC, and V36A/M, T54A, R155K/T/Q, A156S, A156V/T, and V170A for TLV.⁴⁹ The study of these variants is important, particularly for naïve patients, for whom the presence of resistance variants at baseline can reach 18%, and for HIV coinfecting patients who are at increased risk of having one of these variants.⁵⁰

The overall scenario does not seem as good as that offered with the newer nucleotide analogue NS5B polymerase inhibitors. However, until industry, government, and medical scientific societies provide certainty about the worldwide availability and the prices are affordable for most of the infected populations, most patients will be treated with the currently available options.

Future research is needed to optimize the economic resources. The current recommendations are based on lowering the risk of AEs and providing a better SVR, but there is not enough information about the strategies needed to identify the best candidates to receive PR. Those who have experience treatment failure can be offered PI+PR, and the newer and more expensive drugs could be an alternative for other patients. We consider that 3 years of using the PIs BOC and TLV are of limited experience, and a very difficult scenario to be categorical about the use (or not) of new drugs for the treatment of HCV infection.

This meta-analysis has some limitations. Some of the trials involved selected populations, observational studies were included in the secondary outcomes, heterogeneity could be an issue in some outcomes, and only studies written in English were included.

CONCLUSION

This systematic review and meta-analysis supports the superiority of any of the first-generation

PIs for achieving an SVR in patients with genotype 1 HCV infection. We propose that patients previously exposed to PR are good candidates to receive these drugs. We have identified variables that should help the clinician select the best candidates for newer treatments, which will offer real-life alternatives in scenarios not yet covered by clinical guidelines.

ABBREVIATIONS

- **AE:** adverse event.
- **BOC:** boceprevir.
- **CI:** confidence interval.
- **DAA:** direct-acting antiviral.
- **HCV:** hepatitis C virus.
- **HIV:** human immunodeficiency virus.
- **NNH:** number needed to harm.
- **PI:** protease inhibitor.
- **PR:** pegylated interferon plus ribavirin.
- **RCT:** randomized controlled trial.
- **RR:** risk ratio.
- **SVR:** sustained virological response.
- **TLV:** telaprevir.
- **TSA:** trial sequential analysis.

GRANTS

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

ACKNOWLEDGMENTS

Nahum Méndez-Sánchez was part of the National Advisory Board of Merck until 2013. All other authors declare no conflict of interest. This work was supported by Medica Sur Clinic & Foundation.

REFERENCES

1. Guidelines for the screening, care and treatment of persons with hepatitis infection. World Health Organization 2014. Available at: www.who.int/about/licensing/copyright_form/en/index.html.
2. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. *N Engl J Med* 2014; 370: 1869-71.
3. AASLD and IDSA Launch Web-Based Recommendations for Testing, Managing, and Treating HCV. AASLD 2014.
4. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. *J Viral Hepat* 2014; 21: 348-56.
5. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterfer-

- on/ribavirin obviates a protease inhibitor. *Hepatology* 2014; 59: 71-7.
6. Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. *J Clin Pharm Ther* 2014; 39: 14-24.
 7. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. *PLoS One* 2014; 9: e94542.
 8. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. *Ann Intern Med* 2013; 158: 114-23.
 9. Lawitz EJ, Membreno FE. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects. *J Gastroenterol Hepatol* 2014; 29 (8): 1574-81 doi: 10.1111/jgh.12632.
 10. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology* 2006; 43: 954-60.
 11. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: d5928.
 12. G.A.W. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
 13. Thorlund K. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011, p. 1-115.
 14. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeiser T, Bronowicki JP, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; 360: 1839-50.
 15. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, et al. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; 362: 1292-303.
 16. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009; 360: 1827-38.
 17. Sulkowski M. Telaprevir in Combination with Peginterferon Alfa- 2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results. *Hepatology* 2012; 56: 1144A.
 18. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1207-17.
 19. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1195-206.
 20. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; 364: 2405-16.
 21. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011; 365: 1014-24.
 22. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; 364: 2417-28.
 23. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. *Lancet Infect Dis* 2013; 13: 597-605.
 24. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. *J Hepatol* 2012; 56: 78-84.
 25. Flamm SL, Lawitz E, Jacobson I, Bourliere M, Hezode C, Vierling JM, Bacon BR, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. *Clin Gastroenterol Hepatol* 2013; 11: 81-87, e84; quiz e85.
 26. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. *Ann Intern Med* 2013; 159: 86-96.
 27. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. *J Hepatol* 2014; 60: 78-86.
 28. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. *J Hepatol* 2013; 59: 434-41.
 29. Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, et al. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. *Hawaii J Med Public Health* 2013; 72: 6-13.
 30. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. *Aliment Pharmacol Ther* 2014; 39: 93-103.
 31. Singh G. The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection. *Gastroenterology* 2013; 144: S-1136.
 32. Sulkowski M. Anemia during treatment with peginterferon alfa-2b/ ribavirin with or without boceprevir is associated with higher svr rates: analysis of previously untreated and previous-treatment-failure patients. *J Hepatol* 2011; 54: 594.
 33. Karino Y. Analysis of the optimal TVR dose per weight judging from anemia during PEG-IFN/RBV/TVR combination therapy. *J Hepatol* 2013; 58: S338.
 34. Lawitz E. Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients. *Hepatology* 2012; 56: 1144A.
 35. Purohit T. Is Week 1 (W1) and Week 2 (W2) Monitoring Helpful in Patients Treated for Chronic Hepatitis C With Pegylated Interferon, Ribavirin and a Protease Inhibitor. *Gastroenterology* 2013; 144: S983-S984.
 36. Asahina Y. Serum Interleukin-6 levels during treatment correlate with resistance to Telaprevir based triple therapy in chronic hepatitis C. *J Hepatol* 2013; 58: S321.
 37. Ogawa E. Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with Pegylated Interferon A2b and Ribavirin. *J Hepatol* 2013; 58: S-632.

38. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Fuller C, Perner D, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. *J Clin Virol* 2011; 52: 321-7.
39. Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela-Nogueira CA, Urmenyi TP, Tanuri A, et al. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. *Virology* 2013; 10: 57.
40. Thomas XV. Long-Term Follow-Up Of Chronic Hepatitis C Infected Patients Treated With Telaprevir: Evaluation Of Persistence Of Resistant Variants By Ultra-Deep Sequencing. *J Hepatol* 2011; 54: S490-S491.
41. Pinson P. Dynamics Of Hcv Quasispecies During Telaprevir Treatment Dissected Using Ultra-Deep Pyrosequencing: Treatment Failure In 100% Of Genotype 1a Patients. *J Hepatol* 2012; 56: S614.
42. Volpe JM. Cross-sectional Assessment of Telaprevir and Boceprevir resistance-associated mutations of 500 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US. *Hepatology* 2012; 54: 1144A.
43. Velazquez C. Timing And Characteristics Of Drug Resistance Mutations (Drms) In Chronic Hepatitis C Patients During And After Treatment With Protease Inhibitor Therapy At A Single Centre. *J Hepatol* 2013; 58: S632.
44. Messina E. Amino Acid Change In The Positions Associated With Protease Inhibitors Resistance Is Less Frequent In Genotype 3 Than In Genotype 1 Hcv Natural Strain. *J Hepatol* 2013; 58: S632.
45. Galmozzi. Clinical implications of baseline population sequencing of the NS3 protease in HCV-1 partial or null-responders to Peg-interferon/ribavirin. *Dig Liver Dis* 2013; 45: S54.
46. Cento V. HCV Kinetics And Quasispecies Evolution Within The First Hours Of Telaprevir-Based Triple Therapy In Previously Treated HCV-Patients. *J Hepatol* 2013; 58: S632.
47. Cento V. Correlation Of Early Detection Of Hcv Ns3-Resistance And Virological Failure In Patients Treated With Triple Therapy Including Telaprevir Or Boceprevir. *J Hepatol* 2013; 58: S632.
48. Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. *Viruses* 2012; 4: 3281-302.
49. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. *J Hepatol* 2011; 55: 192-206.
50. Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. *AIDS* 2013; 27: 2485-8.